Effects of Uptake and Efflux Transporter Inhibition on Erythromycin Breath Test Results

Size: px
Start display at page:

Download "Effects of Uptake and Efflux Transporter Inhibition on Erythromycin Breath Test Results"

Transcription

1 nature publishing group Effects of Uptake and Efflux Transporter Inhibition on Erythromycin Breath Test Results LA Frassetto 1, S Poon 2, C Tsourounis 2, C Valera 2 and LZ Benet 3 The erythromycin breath test (EBT) is a standard test used to evaluate the extent of CYP3A4 activity. This study examines whether presumed changes in CYP3A4 activity are in fact related to inhibition of an uptake organic anion transporter using rifampin and inhibition of the efflux hepatic P-glycoprotein transporter using lansoprazole. Three EBT tests in healthy adults were conducted: EBT alone, with lansoprazole, and with rifampin. For all subjects, lansoprazole treatment increased respiratory 14 Cexcretionby þ met/h (P ¼ 0.07) and rifampin decreased 14 Cexcretionby met/h (Po0.001) compared with baseline. Comparing lansoprazole to rifampin, 14 C excretion increased by þ met/h (Po0.001). Only women had significant changes after drug infusion: 14 C excretion after rifampin met/h (P ¼ 0.018) and þ met/h (P ¼ 0.018) after lansoprazole. Relying on EBT without considering transporter interactions can lead to errors in interpreting the degree of CYP3A4 metabolism. The cytochrome P450 (CYP450) family is the major metabolic enzyme system in the liver. CYP3A4 alone is responsible for the metabolism of more than 50% of all drugs sold in the US that are metabolized by the P450 system. 1 Therefore, drugs or chemical substances that cause CYP3A4 inhibition or induction are likely causes for drug drug interactions. The erythromycin breath test (EBT) is the most commonly used noninvasive phenotype probe for CYP3A4. 2 However, marked variability has been found when using EBT to predict metabolism of other CYP3A4 substrates and resulting drug drug interactions. 3 Although it has been recognized recently that a small portion of this variability may be attributed to the polymorphic expression of CYP3A4, we previously hypothesized that the lack of correlation is also owing to effects of the erythromycin uptake and efflux transporters, which alter the quantity of erythromycin available for metabolism. 4 Erythromycin metabolism in the liver initially requires uptake into the cells, which is mediated by organic anion transporting polypeptides (OATPs). 5 After injection, [ 14 C-Nmethyl] erythromycin is partially broken down by CYP3A4 to its N-demethylated metabolite and 14 C-formaldehyde. 14 C- formaldehyde is then predominantly converted to 14 C- formate and finally to radiolabeled 14 C-CO 2, which is exhaled through the lungs (ref. 6; Figure 1). The majority of the unmetabolized parent drug and the N-demethylated metabolites are excreted by the efflux transporter P- glycoprotein (P-gp). An increase in EBT 14 C-CO 2 excretion is considered to be a marker for CYP3A4 induction, whereas a decrease in 14 C- CO 2 excretion is considered to be a marker for CYP3A4 inhibition. But the ability of EBT to predict the metabolism of other CYP3A4 substrates may be compromised if these substrates inhibit uptake or efflux transporters, and could cause misleading interpretation of CYP enzyme activity. We have suggested previously 4 that although the EBT is a useful mechanistic probe, its ability to predict the disposition of CYP3A4 substrates in individual patients will not be successful as erythromycin is a good substrate for both uptake and efflux transporters. Previous studies have suggested that the interaction between membrane transporters and metabolizing enzymes are important in understanding drug metabolism and elimination Rifampin is a potent inhibitor for most of the OATP subtypes, but following single-dose administration has minimal induction effects on CYP3A4 and does not inhibit P-gp. For example, in vitro studies in rat hepatocytes have shown that when the liver uptake transporter OATP was inhibited by rifampin, without any effect on CYP3A4, metabolism of erythromycin was decreased. 6 Lansoprazole 1 Clinical Research Center and Department of Medicine, University of California at San Francisco, San Francisco, CA, USA; 2 Department of Clinical Pharmacy, University of California at San Francisco, San Francisco, CA, USA; 3 Department of Biopharmaceutical Sciences, University of California at San Francisco, San Francisco, CA, USA. Correspondence: LZ Benet (Leslie.Benet@ucsf.edu) Received 18 October 2006; accepted 21 January 2007; published online 14 March doi: /sj.clpt VOLUME 81 NUMBER 6 JUNE

2 Basolateral membrane 14 C-erythromycin QATP QATP CYP3A4 Hepatocyte 14 C-erythromycin H 14 CHO N-demethyl erythromycin Apical membrane (biliary excretion) P-gp P-gp Table 1 Patient characteristics at baseline: mean7sd (range) Item All Males Females N Age (years) 2574 (22 38) 2572 (22 28) 2776 (22 38) Race (C:AA:AP) a 9:2:5 6:1:1 3:1:4 BMI (kg/m 2 ) 2373 (21 30) 2473 (21 30) 2272 (19 24) a AA, African American; AP, Asian-Pacific Islander; BMI, body mass index; C, Caucasian. 14 CO 2 Pulmanory exhalation 14 CO 2 H 14 COOH Figure 1 Hepatocyte transporters and the EBT metabolic pathway; 14 C-CO 2 production from 14 C-erythromycin. is a modest P-gp inhibitor, which at the time of our study was believed to have minimal effects on OATPs and CYP3A4. 11 Increased metabolism of erythromycin in this case would not be due to induced CYP3A4 activity, but rather owing to inhibition of the efflux transporter. Therefore, based on in vitro data, EBT would not be a specific probe for CYP3A4 if transporters were not accounted for during the EBT. Following completion of the studies reported here, and just before submission of this manuscript, Kurnik et al. 12 reported that concomitant administration of the potent investigational P-gp inhibitor tariquidar significantly increased EBT values, as we had predicted. 4 We therefore predict that in humans, when the uptake transporter (OATP) activity is inhibited by rifampin, an apparent decreased CYP3A4 activity will be observed. Conversely, when the efflux transporter (P-gp) is inhibited by lansoprazole, an apparent increased CYP3A4 activity will be observed. Based on our results from in vitro studies, neither drug should actually alter CYP3A4 activity. A better understanding of the transporter effects on EBT would be helpful to evaluate its usefulness as a mechanistic CYP3A4 probe versus its use as a predictor of the disposition of other CYP3A4 substrates. RESULTS Subjects Sixteen healthy adult subjects (eight women and eight men) were enrolled (see Table 1 for patient characteristics). There were no significant differences in age or body mass index between gender groups in this study. No adverse effects or symptoms attributable to erythromycin, lansoprazole, or rifampin occurred. All subjects completed the study according to the study protocol. EBT baseline Among all subjects, the mean baseline EBT was C met/h (range, C met/h). EBT values were significantly higher for female subjects; C met/h (range, C met/h) compared with male subjects; C met/h (range, C met/h; P ¼ 0.014). The EBT changes from baseline following the administration of lansoprazole and rifampin are shown in Figure 2 and Table 2. Lansoprazole and rifampin The mean EBT value for the 16 subjects following lansoprazole administration increased to C met/h (P ¼ 0.07). The mean EBT value for the 16 subjects following rifampin administration was C met/h; significantly lower than the mean baseline EBT C met/h (Po0.001). The mean difference between EBT results with rifampin and with lansoprazole was (Po0.001). Among the eight female subjects receiving lansoprazole, the mean EBT value was C met/h compared with the baseline EBT value C met/h (P ¼ 0.018; Figure 2 and Table 2). The eight male subjects receiving lansoprazole had a mean EBT of C met/h, minimally different from the baseline EBT of C met/h (P ¼ 0.89); four male subjects had increases and four had decreases in 14 C excretion. Among the eight female subjects receiving rifampin, 14 C excretion decreased C met/h (P ¼ 0.018) from baseline (Figure 2 and Table 2). The male subjects also had a decrease from baseline that did not achieve statistical significance of C met/h (P ¼ 0.07; Figure 2 and Table 2). DISCUSSION EBT is believed to provide a noninvasive and easily quantitative means for evaluating hepatic CYP3A activity. However, predictions regarding the clearance of drugs using EBT have been conflicting, with interindividual variability of up to 40%. 3 We hypothesized that discrepancies in previous reports might be owing to membrane transporter influences on drug exposure. 4 In fact, we were able to predict changes in EBT results based on prediction of inhibition of the erythromycin uptake transporter with rifampin and the efflux transporter with lansoprazole. Previous rat in vitro hepatocyte studies and in vivo pharmacokinetic studies with erythromycin demonstrated that erythromycin is a substrate of Oatp1a4 and Oatp1b2 6 CLINICAL PHARMACOLOGY & THERAPEUTICS VOLUME 81 NUMBER 6 JUNE

3 %EBT (met/h) Male EBT+rifampin EBT+lansoprazole Female Figure 2 Changes from baseline in 14 C-CO 2 counts with lansoprazole and rifampin (n ¼ 16). and that modulating uptake and efflux transporters affects intracellular erythromycin concentrations. 6,11 Erythromycin is a good substrate for Oatps; in the presence of rifampin, hepatic intracellular drug decreases 23% and blood erythromycin area under the curve in rats increases 150%. 10 Erythromycin is also a good substrate for P-gp; adding the P-gp inhibitor GG918 in vitro increases rat intrahepatic erythromycin content by 30% and leads to a doubling of the intracellular N-demethyl erythromycin metabolite/parent ratio. 10 In this study, we chose lansoprazole to inhibit P-gp because of its convenient intravenous (i.v.) formulation, minimal side effects, short half-life, and apparent inhibitor specificity. 11 It is approved for human use and was available through the hospital research pharmacy. In in vitro studies in Caco-2 and MDR-1 transfected LLC-PK1 cells, lansoprazole is a substrate, and a P-gp inhibitor. 11 Although we did not measure lansoprazole levels, published reports of i.v. lansoprazole C max levels after a 30-mg i.v. dose approach the IC Greater erythromycin metabolism with lansoprazole may be due to its inhibition of P-gp-mediated erythromycin excretion, leading to increased intracellular erythromycin available for 14 C-N-demethylation. The traditional explanation might suggest that lansoprazole is inducing CYP3A4. Conversely, decreased erythromycin metabolism with rifampin may be due to its inhibition of OATP-mediated erythromycin uptake, leading to less intracellular erythromycin available for 14 C-N-demethylation and lower 14 C-CO 2 compared to baseline, as was seen in this study. After repeated doses, rifampin is an inducer of CYP3A4; the traditional explanation would predict that 14 C-CO 2 should be higher. Although we did not observe a statistically significant difference in EBT values among all subjects receiving lansoprazole, we did observe a statistically significant difference in female subjects. In contrast, Kurnik et al., 12 in a very recent paper, found an increase in 14 C-erythromycin excretion in all eight Caucasian male subjects given the highly potent and selective investigational P-gp inhibitor tariquidar. The evidence of P-gp inhibition with tariquidar and the in vitro P-gp inhibition observed with lansoprazole, which did not translate equally in vivo, suggests that P-gp differences may account for the differences in EBT values that we observed among male and female subjects. Our study was not specifically powered to look at EBT variability between male and female subjects. However, sex effects on EBT were seen after lansoprazole and rifampin administration. Previous studies have examined sex disparities as one of the reasons for causing conflicting reports in EBT. Many have suggested sex differences with higher female metabolism and clearance compared with male subjects for CYP3A and P-gp substrates. 14,15 We hypothesized that literature data may be consistent with the supposition that sex differences in the clearance of CYP3A4 substrates may be related to differences in liver P-gp activity between male and female subjects, 1,13 as had been reported by Schuetz et al. 16 However, subsequent evaluation of liver bank measurements of CYP3A4 and P-gp reported no sex-related differences in P-gp, but rather higher levels of CYP3A4 in women. 17 Our Table 2 EBT at baseline and after rifampin and lansoprazole ( 14 C met/h) All P-value Males P-value Females P-value Baseline EBT D Rifampin from baseline o D Lansoprazole from baseline D Rifampin versus lansoprazole o o EBT, erythromycin breath test. 830 VOLUME 81 NUMBER 6 JUNE

4 present EBT results with lansoprazole versus rifampin suggest that sex-related differences in hepatic P-gp activity or response to inhibitors (possibly as opposed to P-gp hepatic amounts) should be re-examined in sex-related differences in the clearance of CYP3A4/P-gp dual substrates. Sex differences in hepatic OATP have been described in both human and animal models. These differences have been related to transporter mrna, protein expression, and the presence of gonadal hormones. 18 In our analysis, we found that both male and female subjects receiving rifampin had decreased 14 C-CO 2 production, and that the change did not reach statistical significance in male subjects (P ¼ 0.077), but did in female subjects (P ¼ 0.018). Overall, the decrease was highly significant in men and women (Po0.001). Limitations of the study One limitation of this study was the small sample size, which was calculated for the group as a whole. Based on these data, a larger group of male subjects would be needed to investigate the effects of various P-gp inhibitors on erythromycin metabolism during EBT. A second limitation of the study was that a concomitant CYP3A4 probe, not a substrate or inhibitor of an OATP or P- gp, was not given. Thus, it is possible that lansoprazole or rifampin could have altered CYP3A metabolism, independent of their effects on erythromycin uptake or efflux. However, 20 min is generally considered too short a time for enzyme upregulation or downregulation, although activation is a remote possibility. Subsequent to our clinical study, Maréchal et al. 19 reported that the IC 50 inhibition of CYP3A4 metabolism of a fluorescent probe, P4 BFC ¼ 7-benzyloxy- 4-trifluoromethylcoumarin, was less than that reported for P-gp inhibition, 11 although as stated earlier, our preliminary in vitro studies did not show lansoprazole to be an inhibitor of erythromycin metabolism. Furthermore, if lansoprazole were inhibiting erythromycin metabolism, we would have seen a decrease in 14 C-CO 2 production. We did not measure lansoprazole or rifampin levels in this study. The doses used were standard clinical doses for these medications. Also, we did not genotype the subjects enrolled in this study. Differences in metabolism owing to differences in transporter activity from polymorphisms may be important in evaluating EBT activity. But the purpose of this study was to show that transporter dynamics can affect EBT, which we have demonstrated without genotyping. CONCLUSION The EBT appears to be a very useful probe to evaluate mechanistic changes in CYP3A4 metabolism, used here to evaluate the effects of uptake and efflux transporters on CYP3A4 metabolism of erythromycin. We have shown in vivo in humans that inhibition of OATP decreases CYP3A4 metabolism and that P-pg inhibition increases CYP3A4 erythromycin metabolism, but only in female subjects. This latter finding raises again the question as to whether P-gp or CYP3A4 hepatic activity levels are responsible for the increased clearance of CYP3A4/P-gp substrates in female versus male subjects as also observed here with EBT, and suggests that P-gp sex differences may be responsible, as we have previously hypothesized. 1 However, the effects of transporters on EBT will compromise the ability of EBT to be a predictor of the clearance of other CYP3A4 drugs in patients. 4 MATERIALS AND METHODS Subjects. Healthy, nonsmoking subjects on no medications were recruited for this study. All subjects underwent a screening evaluation that included a medical history, physical exam, and blood and urine tests (hemoglobin b, hematocrit, white blood cells with differential, platelets, Na þ, K þ, HCO 3, Cl, AST, ALT, alkaline phosphatase, total bilirubin, glucose, creatinine, BUN, albumin, UA with microscopic analysis, and a serum pregnancy test for female subjects of child-bearing potential). The University of California San Francisco (UCSF) Institutional Review Board approved the study and all subjects provided written informed consent. Subjects who were sexually active consented to use two forms of birth control: condoms with each sexual encounter for men; cervical caps, diaphragms, and/or a nonhormonal intrauterine device for women. Any subject using other methods of birth control such as oral contraceptive pills, hormonal patches or vaginal rings, hormonal implants, injections, or hormonal intrauterine devices were excluded. Subjects were instructed to abstain from consuming grapefruit, grapefruit juice, and/or alcoholic beverages, over-thecounter medications and herbal products. Subjects were allowed to drink or eat caffeinated beverages/food except on study visit days. Study design. This was an open-label, randomized, crossover study. Each subject received an EBT at visits 1 3 after being admitted to the UCSF Clinical Research Center. During visit 1, the subjects received only an EBT. Each EBT was separated by at least 1 week. During visit 2, subjects were randomized to either an i.v. infusion of rifampin 600 mg or lansoprazole 30 mg over 30 min followed by an i.v. bolus of erythromycin via a separate i.v. catheter at the end of each infusion; the alternative solution was infused during visit 3. Intravenous rifampin and lansoprazole were prepared by the inpatient research pharmacy; rifampin was prepared as 600 mg in 100 ml D5W and lansoprazole was prepared in 100 ml D5W. Randomization was by odd even random number draw, adjusted so that for the 16 subjects, eight received one treatment first and eight received the alternate. Neither subjects nor study investigators were blinded to randomization. Erythromycin breath test: administration. Three micro Curies of [ 14 C-N-methyl] erythromycin alcohol (0.008 mg erythromycin in 0.5 ml alcohol) were mixed with 4.5 ml D5W just before administration. Each subject was slowly injected with this 14 C-erythromycin solution over 60 s. The breath samples were collected 20 min after the entire 14 C-erythromycin dose was injected. Patients were instructed to exhale normally into the collection balloon until the balloon was full; two balloons were collected at each test. Analysis. Each of the 20-min breath test samples obtained from study volunteers and their corresponding [ 14 C-N-methyl] erythromycin dose vials were sent to Metabolic Solutions (Amherst, NH) for analysis. Approximately 2 mmol 14 C-CO 2 were analyzed from each balloon. The radioactivity contained in the 20-min EBTs and the vials were measured with a Packard 2100TR Liquid Scintillation counter and expressed in units of disintegrations per minute (d.p.m.). CLINICAL PHARMACOLOGY & THERAPEUTICS VOLUME 81 NUMBER 6 JUNE

5 The percentage of administered [ 14 C-N-methyl] erythromycin metabolized and exhaled as 14 C-CO 2 /min was calculated directly from the d.p.m. of the 20-min EBT. According to Metabolic Solutions, the EBT assumes an endogenous CO 2 production equal to 5 mmol CO 2 /m 2 body surface area (BSA)/min and 3 mci (or d.p.m.) injected. The radioactivity administered must be corrected to account for residual amounts of [ 14 C-N-methyl] erythromycin left behind in the vials. In consideration of these factors, the following equation calculates the percent of the initial [ 14 C-N-methyl] erythromycin dose metabolized per minute from each subject s 20-min EBT: ½ 14 C-N-methylŠ erythromycin dose metabolized=minute ¼ ½ðdpm at 20 minþð5 mmol CO 2 =m 2 = min ½BSAðm 2 ÞŠÞ=2mmolCO 2 ð6: % d:p:m: left in vialþ The final EBT result was reported as the % [ 14 C-N-methyl] erythromycin exhaled per hour based on % [ 14 C-N-methyl] erythromycin dose metabolized per minute. This was done by using the validated equation below, developed by Wagner: 20 %½ 14 C-N-methylŠ erythromycin metabolized=h ¼ð 65:988x 2 þ 54:645x þ 0:0377Þ where x is the % dose metabolized/min after 20-min EBT. EBT interpretation. For all 16 study participants, three sets of EBT data were generated from the three GCRC study visits (visits 1 3). The EBT results for visits 2 and 3 after rifampin and lansoprazole exposure were compared with baseline activity measurements from visit 1. Repeated measures analysis of variance was used to evaluate the significance of experimental results with post hoc analyses carried out using paired t-tests (Sigmastat, San Rafael, CA). Data are reported as mean7sd. ACKNOWLEDGMENTS We acknowledge the help of the staff at the UCSF General Clinical Research Center (M ), without which this study could not have been accomplished. This study was supported in part by NIH Grant HD CONFLICT OF INTEREST The authors declared no conflict of interest. & 2007 American Society for Clinical Pharmacology and Therapeutics 1. Cummins, C.L., Wu, C.Y. & Benet, L.Z. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin. Pharmacol. Ther. 75, (2002). 2. Watkins, P.B. et al. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. J. Clin. Invest. 83, (1989). 3. Rivory, L.P. Erythromycin breath test. Clin. Pharmacol. Ther. 70, (2001). 4. Benet, L.Z. There are no useful CYP3A probes that quantitatively predict the in vivo kinetics of other CYP3A substrates and no expectation that one will be found. Mol. Interv. 5, (2005). 5. Baker, A.L., Kotake, A.N. & Schoeller, D.A. Clinical utility of breath tests for the assessment of hepatic function. Semin. Liver Dis. 3, (1983). 6. Sun, H., Huang, Y., Frassetto, L. & Benet, L.Z. Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab. Dispos. 32, (2004). 7. Wu, C.Y. & Benet, L.Z. Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and GG918. Drug Metab. Dispos. 31, (2003). 8. Lau, Y.Y, Wu, C.Y., Okochi, H. & Benet, L.Z. Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay. J. Pharmacol. Exp. Ther. 308, (2003). 9. Lam, J.L. & Benet, L.Z. Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. Drug Metab. Dispos. 32, (2004). 10. Lam, J.L., Okochi, H., Huang, Y. & Benet, L.Z. In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter-enzyme interplay. Drug Metab. Dispos. 34, (2006). 11. Pauli-Magnus, C., Rekersbrink, S., Klotz, U. & Fromm, M.F. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn-Schmiedeberg s Arch. Pharmacol. 364, (2001). 12. Kurnik, D., Wood, A.J.J. & Wilkinson, G.R. The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity. Clin. Pharmacol. Ther. 80, (2006). 13. Freston, J.W. et al. Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole. Aliment. Pharmacol. Ther. 19, (2004). 14. Meibohm, B., Beierle, I. & Derendorf, H. How important are gender differences in pharmacokinetics? Clin. Pharmacokinet. 41, (2002). 15. Benet, L.Z., Cummins, C.L. & Wu, C.Y. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int. J. Pharm. 277, 3 9 (2004). 16. Schuetz, E.G., Furuya, K.N. & Schuetz, J.D. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J. Pharmacol. Exp. Ther. 275, (1995). 17. Wolbold, R. et al. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38, (2003). 18. Morris, M.E., Lee, H.J. & Predko, L.M. Gender differences in the membrane transport of endogenous and exogenous compounds. Pharmacol. Rev. 55, (2003). 19. Maréchal, J.-D. et al. In silico and in vitro screening for inhibition of cytochrome P450 CYP3A4 by comedications commonly used by patients with cancer. Drug Metab. Dispos. 34, (2006). 20. Wagner, D. CYP3A4 and the erythromycin breath test. Clin. Pharmacol. Ther. 63, (1998). 832 VOLUME 81 NUMBER 6 JUNE

Exploiting BDDCS and the Role of Transporters

Exploiting BDDCS and the Role of Transporters Exploiting BDDCS and the Role of Transporters (Therapeutic benefit of scientific knowledge of biological transporters, understanding the clinical relevant effects of active transport on oral drug absorption)

More information

Biopharmaceutics Drug Disposition Classification System (BDDCS) --- Its Impact and Application

Biopharmaceutics Drug Disposition Classification System (BDDCS) --- Its Impact and Application Biopharmaceutics Drug Disposition Classification System (BDDCS) --- Its Impact and Application Leslie Z. Benet, Ph.D. Professor of Bioengineering and Therapeutic Sciences Schools of Pharmacy and Medicine

More information

Biopharmaceutics Drug Disposition Classification System (BDDCS) and Its Application in Drug Discovery and Development

Biopharmaceutics Drug Disposition Classification System (BDDCS) and Its Application in Drug Discovery and Development Biopharmaceutics Drug Disposition Classification System (BDDCS) and Its Application in Drug Discovery and Development Leslie Z. Benet, Ph.D. Professor of Bioengineering and Therapeutic Sciences University

More information

Erik Mogalian, Polina German, Chris Yang, Lisa Moorehead, Diana Brainard, John McNally, Jennifer Cuvin, Anita Mathias

Erik Mogalian, Polina German, Chris Yang, Lisa Moorehead, Diana Brainard, John McNally, Jennifer Cuvin, Anita Mathias Evaluation of Transporter and Cytochrome P450-Mediated Drug-Drug Interactions Between Pan-Genotypic HCV NS5A Inhibitor GS-5816 and Phenotypic Probe Drugs Erik Mogalian, Polina German, Chris Yang, Lisa

More information

Basic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics

Basic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics Basic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics Learning Outcomes Define biopharmaceutics Describe 4 processes of pharmacokinetics Describe factors that affect medication absorption Describe

More information

Yvonne Y. Lau, Hideaki Okochi, Yong Huang, and Leslie Z. Benet

Yvonne Y. Lau, Hideaki Okochi, Yong Huang, and Leslie Z. Benet 0090-9556/06/3407-1175 1181$20.00 DRUG METABOLISM AND DISPOSITION Vol. 34, No. 7 Copyright 2006 by The American Society for Pharmacology and Experimental Therapeutics 9076/3121398 DMD 34:1175 1181, 2006

More information

T Eley, Y-H Han, S-P Huang, B He, W Li, W Bedford, M Stonier, D Gardiner, K Sims, P Balimane, D Rodrigues, RJ Bertz

T Eley, Y-H Han, S-P Huang, B He, W Li, W Bedford, M Stonier, D Gardiner, K Sims, P Balimane, D Rodrigues, RJ Bertz IN VIVO AND IN VITRO ASSESSMENT OF ASUNAPREVIR (ASV; BMS-650032) AS AN INHIBITOR AND SUBSTRATE OF ORGANIC ANION TRANSPORT POLYPEPTIDE (OATP) TRANSPORTERS IN HEALTHY VOLUNTEERS T Eley, Y-H Han, S-P Huang,

More information

Effect of Multiple-Dose Ketoconazole and the Effect of Multiple-Dose Rifampin on Pharmacokinetics (PK) of the HCV NS3 Protease Inhibitor Asunaprevir

Effect of Multiple-Dose Ketoconazole and the Effect of Multiple-Dose Rifampin on Pharmacokinetics (PK) of the HCV NS3 Protease Inhibitor Asunaprevir Effect of Multiple-Dose Ketoconazole and the Effect of Multiple-Dose Rifampin on Pharmacokinetics (PK) of the HCV NS3 Protease Inhibitor Asunaprevir Eley T, 1 He B, 1 Huang S-P, 2 Stonier M, 1 Bedford

More information

Leslie Z. Benet, PhD. Professor of Bioengineering and Therapeutic Sciences Schools of Pharmacy and Medicine University of California San Francisco

Leslie Z. Benet, PhD. Professor of Bioengineering and Therapeutic Sciences Schools of Pharmacy and Medicine University of California San Francisco Biopharmaceutics Drug Disposition Classification System (BDDCS) and Drug Interactions Leslie Z. Benet, PhD Professor of Bioengineering and Therapeutic Sciences Schools of Pharmacy and Medicine University

More information

Using Accelerator Mass Spectrometry to Explain the Pharmacokinetics of Vismodegib Cornelis E.C.A. Hop

Using Accelerator Mass Spectrometry to Explain the Pharmacokinetics of Vismodegib Cornelis E.C.A. Hop Using Accelerator Mass Spectrometry to Explain the Pharmacokinetics of Vismodegib Cornelis E.C.A. Hop Topics to be Addressed Why AMS? AMS for mass balance studies with vismodegib AMS for absolute bioavailability

More information

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of

More information

Cytochrome P450 Drug Interaction Table Flockhart Table

Cytochrome P450 Drug Interaction Table Flockhart Table Cytochrome P450 Drug Interaction Table Flockhart Table The table contains lists of drugs in columns under the designation of specific cytochrome P450 isoforms. CYTOCHROME P450 DRUG INTERACTION TABLE A

More information

Complexities of Hepatic Drug Transport: How Do We Sort It All Out?

Complexities of Hepatic Drug Transport: How Do We Sort It All Out? Complexities of Hepatic Drug Transport: How Do We Sort It All Out? Keith A. Hoffmaster Pfizer Research Technology Center Cambridge, MA NEDMDG 2005 Summer Symposium 06.08.2005 The Challenge Intestinal uptake

More information

Suitability of Digoxin as a P Glycoprotein Probe: Implications of Other Transporters on Sensitivity and Specificity

Suitability of Digoxin as a P Glycoprotein Probe: Implications of Other Transporters on Sensitivity and Specificity Review Suitability of Digoxin as a P Glycoprotein Probe: Implications of Other Transporters on Sensitivity and Specificity The Journal of Clinical Pharmacology XX(XX) 1 11 2013, The American College of

More information

Core Data Set CYP2D6 Metabolism

Core Data Set CYP2D6 Metabolism Core Data Set CYP2D6 Metabolism Oxidised metabolites seen in pre-clinical species Inhibitor Target CYP Isoform CLint (µl/min/mg protein) % Inhibition Control 12.5 - Furafylline 1A2 12.9 0 Sulfaphenoxazole

More information

A unified in vivomodelingapproach for quantitative prediction of the impact of gene polymorphism and drug interactions on drug exposure

A unified in vivomodelingapproach for quantitative prediction of the impact of gene polymorphism and drug interactions on drug exposure A unified in vivomodelingapproach for quantitative prediction of the impact of gene polymorphism and drug interactions on drug exposure Sylvain Goutelle, Michel Tod, Laurent Bourguignon, Nathalie Bleyzac,

More information

Section 5.2: Pharmacokinetic properties

Section 5.2: Pharmacokinetic properties Section 5.2: Pharmacokinetic properties SmPC training presentation Note: for full information refer to the European Commission s Guideline on summary of product characteristics (SmPC) SmPC Advisory Group

More information

The Future of In Vitro Systems for the Assessment of Induction and Suppression of Enzymes and Transporters

The Future of In Vitro Systems for the Assessment of Induction and Suppression of Enzymes and Transporters The Future of In Vitro Systems for the Assessment of Induction and Suppression of Enzymes and Transporters AAPS, San Diego November 6 th, 2014 Andrew Parkinson, XPD Consulting Lisa Almond, Simcyp-Certara

More information

Applied Biopharmaceutics & Pharmacokinetics Sixth Edition

Applied Biopharmaceutics & Pharmacokinetics Sixth Edition Applied Biopharmaceutics & Pharmacokinetics Sixth Edition Hill Leon Shargel, PHD, RPh Applied Biopharmaceutics, LLC Raleigh, North Carolina Affiliate Associate Professor, School of Pharmacy Virginia Commonwealth

More information

Evaluation of Drug-Drug Interactions FDA Perspective

Evaluation of Drug-Drug Interactions FDA Perspective Evaluation of Drug-Drug Interactions FDA Perspective Kellie Schoolar Reynolds, Pharm.D. Deputy Director Division of Clinical Pharmacology IV Office of Clinical Pharmacology Office of Translational Sciences

More information

RISK FACTORS AND DRUG TO STATIN-INDUCED MYOPATHY

RISK FACTORS AND DRUG TO STATIN-INDUCED MYOPATHY RISK FACTORS AND DRUG INTERACTION PREDISPOSING TO STATIN-INDUCED MYOPATHY Assist. Prof. Dr. Verawan Uchaipichat Clinical Pharmacy Department Khon Kaen University Advanced Pharmacotherapy 2012 Updated d

More information

Cryo Characterization Report (CCR)

Cryo Characterization Report (CCR) Human Cryopreserved Hepatocytes Lot number: HUM4061B Date: October 19, 2014 Cryo Characterization Report (CCR) Lot Overview Qualification Catalog Number Quantity Cryopreserved human hepatocytes, Qualyst

More information

Bristol-Myers Squibb HCV DAAs: Review of Interactions Involving Transporters. Timothy Eley. 21 May 2014

Bristol-Myers Squibb HCV DAAs: Review of Interactions Involving Transporters. Timothy Eley. 21 May 2014 Bristol-Myers Squibb HCV DAAs: Review of Interactions Involving Transporters Timothy Eley 15th HIV/HEPPK Workshop 21 May 2014 Disclosures T Eley is a full time employee and stockholder of Bristol-Myers

More information

Strategy on Drug Transporter Investigation Why, How, Which & When. Jasminder Sahi

Strategy on Drug Transporter Investigation Why, How, Which & When. Jasminder Sahi Strategy on Drug Transporter Investigation Why, How, Which & When Jasminder Sahi Intestine Drug Absorption PEPT1 OATPs MCTs AE2 Epithelial Cell MCTs MRP3 Liver Excretion via Liver Kidney MRPs OATPs N PT1

More information

CYP2D6: mirtazapine 2001/2002/2003

CYP2D6: mirtazapine 2001/2002/2003 CYP2D6: mirtazapine 2001/2002/200 Cl or = oral clearance,=c ss = steady state concentration, EM = extensive metaboliser, IM = intermediate metaboliser, MR = metabolic ratio, NS = non-significant, PM =

More information

Itraconazole and Clarithromycin as Ketoconazole Alternatives for Clinical CYP3A Inhibition Studies to Quantify Victim DDI Potential

Itraconazole and Clarithromycin as Ketoconazole Alternatives for Clinical CYP3A Inhibition Studies to Quantify Victim DDI Potential Itraconazole and Clarithromycin as Ketoconazole Alternatives for Clinical CYP3A Inhibition Studies to Quantify Victim DDI Potential Alice Ban Ke, Ph.D. Consultant & Scientific Advisor Simcyp Limited Alice.Ke@certara.com

More information

Comparison Between the US FDA, Japan PMDA and EMA In Vitro DDI Guidance: Are we Close to Harmonization?

Comparison Between the US FDA, Japan PMDA and EMA In Vitro DDI Guidance: Are we Close to Harmonization? Comparison Between the US FDA, Japan PMDA and EMA In Vitro DDI Guidance: Are we Close to Harmonization? Brian Ogilvie, Ph.D. VP Scientific Consulting XenoTech, LLC bogilvie@xenotechllc.com 14 Jun, 2018

More information

EVIDENCE FOR THE VALIDITY OF CORTISOL

EVIDENCE FOR THE VALIDITY OF CORTISOL 0090-9556/03/3111-1283 1287$7.00 DRUG METABOLISM AND DISPOSITION Vol. 31, No. 11 Copyright 2003 by The American Society for Pharmacology and Experimental Therapeutics 1129/1100488 DMD 31:1283 1287, 2003

More information

BIOPHARMACEUTICS and CLINICAL PHARMACY

BIOPHARMACEUTICS and CLINICAL PHARMACY 11 years papers covered BIOPHARMACEUTICS and CLINICAL PHARMACY IV B.Pharm II Semester, Andhra University Topics: Absorption Distribution Protein binding Metabolism Excretion Bioavailability Drug Interactions

More information

3. P450 Drug Metabolism DDIs: Induction

3. P450 Drug Metabolism DDIs: Induction 35 3. P450 Drug Metabolism DDIs: Induction General Introductiona and Definition of a DDI: A drug-drug interaction (DDI) occurs when two drugs, each of which is safe and efficacious alone at their respective

More information

DRUG METABOLISM AND PHARMACOKINETICS (DMPK) Lena Gustavsson, H. Lundbeck A/S, November 2015

DRUG METABOLISM AND PHARMACOKINETICS (DMPK) Lena Gustavsson, H. Lundbeck A/S, November 2015 DRUG METABOLISM AND PHARMACOKINETICS (DMPK), H. Lundbeck A/S, LEGU@lundbeck.com November 2015 DMPK in Drug Discovery and Development Agenda Introduction Optimizing pharmacokinetic properties Absorption

More information

Strategies for Developing and Validating PBPK Models for Extrapolation to Unstudied Population

Strategies for Developing and Validating PBPK Models for Extrapolation to Unstudied Population Strategies for Developing and Validating PBPK Models for Extrapolation to Unstudied Population Nina Isoherranen Department of Pharmaceutics University of Washington Processes driving drug disposition are

More information

INTERPLAY BETWEEN P-GLYCOPROTEIN-MEDIATED EFFLUX AND CYTOCHROME P4503A-MEDIATED METABOLISM IN THE INTESTINE

INTERPLAY BETWEEN P-GLYCOPROTEIN-MEDIATED EFFLUX AND CYTOCHROME P4503A-MEDIATED METABOLISM IN THE INTESTINE INTERPLAY BETWEEN P-GLYCOPROTEIN-MEDIATED EFFLUX AND CYTOCHROME P4503A-MEDIATED METABOLISM IN THE INTESTINE Beverly M. Knight A dissertation submitted to the faculty of the University of North Carolina

More information

Pharmacogenomics and Pharmacokinetics ^

Pharmacogenomics and Pharmacokinetics ^ Pharmacogenomics and Pharmacokinetics ^ avid F. Kisor, B.S., Pharm.. Profeor of Pharmacokinetics epartment of Pharmaceutical and Biomedical Sciences Raabe College of Pharmacy Ohio Northern University Learning

More information

BASIC PHARMACOKINETICS

BASIC PHARMACOKINETICS BASIC PHARMACOKINETICS MOHSEN A. HEDAYA CRC Press Taylor & Francis Croup Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Group, an informa business Table of Contents Chapter

More information

Patients must have met all of the following inclusion criteria to be eligible for participation in this study.

Patients must have met all of the following inclusion criteria to be eligible for participation in this study. Supplementary Appendix S1: Detailed inclusion/exclusion criteria Patients must have met all of the following inclusion criteria to be eligible for participation in this study. Inclusion Criteria 1) Willing

More information

Drug Interactions, from bench to bedside

Drug Interactions, from bench to bedside Drug Interactions, from bench to bedside Candidate to Market, The Paterson Institute for Cancer Research, Manchester, UK Michael Griffin PhD Overview of presentation To understand the importance of drug-drug

More information

To understand the formulary process from the hospital perspective

To understand the formulary process from the hospital perspective Formulary Process Michael A. Militello, Pharm.D. Cleveland Clinic Cleveland Clinic 2011 Goal and Objectives To understand the formulary process from the hospital perspective p To list the various panels

More information

Effects of Liver Disease on Pharmacokinetics

Effects of Liver Disease on Pharmacokinetics Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program October 31, 2013 National Institutes of Health Clinical Center 1 GOALS of Effects of Liver

More information

Genetics and Genomics: Influence on Individualization of Medication Regimes

Genetics and Genomics: Influence on Individualization of Medication Regimes Genetics and Genomics: Influence on Individualization of Medication Regimes Joseph S Bertino Jr., Pharm.D., FCCP Schenectady, NY USA Goals and Objectives To discuss pharmacogenetics and pharmacogenomics

More information

Pharmacogenetics and Pharmacokinetics

Pharmacogenetics and Pharmacokinetics Chapter 2 Pharmacogenetics and Pharmacokinetics Mauro Saivezzo/ShutterStock, Inc. L earning O bjectives Upon completion of this chapter, the student will be able to: 1. Recognize the influence of genetic

More information

FDA s Clinical Drug Interaction Studies Guidance (2017 Draft Guidance)

FDA s Clinical Drug Interaction Studies Guidance (2017 Draft Guidance) FDA s Clinical Drug Interaction Studies Guidance (2017 Draft Guidance) Kellie S. Reynolds, Pharm.D. Deputy Director, Division of Clinical Pharmacology IV Office of Clinical Pharmacology (OCP) Office of

More information

Regulation of the cell surface expression and transport capacity of BSEP by small chemical molecules

Regulation of the cell surface expression and transport capacity of BSEP by small chemical molecules Regulation of the cell surface expression and transport capacity of by small chemical molecules Hisamitsu Hayashi and Yuichi Sugiyama Dept. of Molecular Pharmacokinetics, Graduate School of Pharmaceutical

More information

Evaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans

Evaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans Supplement Article Evaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans The Journal of Clinical Pharmacology (2016), 56(S7) S82 S98 C 2016, The

More information

GSK , 2.0, 18, 2014, DAIDS

GSK , 2.0, 18, 2014, DAIDS Letter of Amendment # 1 to: HPTN 077: A Phase IIa Study to Evaluate the, Tolerability and Pharmacokinetics of the Investigational Injectable HIV Integrase Inhibitor, GSK1265744, in HIV-uninfected Men and

More information

Falk Symposium 156: Genetics in Liver Disease. Pharmacogenetics. Gerd Kullak-Ublick

Falk Symposium 156: Genetics in Liver Disease. Pharmacogenetics. Gerd Kullak-Ublick Falk Symposium 156: Genetics in Liver Disease Pharmacogenetics Gerd Kullak-Ublick Division of Clinical Pharmacology and Toxicology Department of Internal Medicine University Hospital Zurich Freiburg, 8.

More information

SYNOPSIS. Trial Identification and Protocol Summary

SYNOPSIS. Trial Identification and Protocol Summary 1 SYNOPSIS Trial Identification and Protocol Summary Company: Tibotec Pharmaceuticals Ltd (now Tibotec Pharmaceuticals) Trade Name: Prezista Indication: HIV-1 infection Title: Drug Substance: TMC114 Trial

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

A Clinically Significant Interaction Between Tacrolimus and Multiple Proton Pump Inhibitors in a Kidney Transplant Recipient

A Clinically Significant Interaction Between Tacrolimus and Multiple Proton Pump Inhibitors in a Kidney Transplant Recipient Cedarville University DigitalCommons@Cedarville Pharmacy Practice Faculty Publications Department of Pharmacy Practice - A Clinically Significant Interaction Between Tacrolimus and Multiple Proton Pump

More information

Caveat: Validation and Limitations of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters

Caveat: Validation and Limitations of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters Caveat: Validation and Limitations of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters Uwe Fuhr, University Hospital Cologne 1 How to Safeguard that Metrics Reflect E/T Activity? in healthy

More information

Transporters DDI-2018

Transporters DDI-2018 Transporters DDI-2018 Mark S. Warren, Ph.D. June 16, 2018 Senior Director of Assay Services DDI-2018: 21 st Conference on DDIs FDA guidance documents: A 21 year history 1997 2006 2012 2017 Each year, large

More information

SILOFAST Capsules (Silodosin)

SILOFAST Capsules (Silodosin) Published on: 10 Jul 2014 SILOFAST Capsules (Silodosin) Composition SILOFAST-4 Capsules Each hard gelatin capsule contains: Silodosin 4 mg Approved colours used in capsule shell SILOFAST-8 Capsules Each

More information

Constitutive Regulation of P450s by Endocrine Factors

Constitutive Regulation of P450s by Endocrine Factors References: Constitutive Regulation of P450s by Endocrine Factors Meyer UA. Endo-xenobiotic crosstalk and the regulation of cytochromes P450. Drug Metab Rev 39:639-46, 2007. Waxman DJ and O Connor C. Growth

More information

Introduction to. Pharmacokinetics. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

Introduction to. Pharmacokinetics. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D Introduction to 1 Pharmacokinetics University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 2 Learning objectives Understand compartment models and how they effects

More information

Clinical Pharmacology of DAA s for HCV: What s New & What s In Pipeline

Clinical Pharmacology of DAA s for HCV: What s New & What s In Pipeline Clinical Pharmacology of DAA s for HCV: What s New & What s In Pipeline Kirk Bertelsen, PhD Clinical Pharmacology Janssen Pharmaceuticals, Research & Development 4/24/2013 1 Incivo Simeprevir 2 Janssen

More information

NIH Public Access Author Manuscript Transplant Proc. Author manuscript; available in PMC 2011 April 6.

NIH Public Access Author Manuscript Transplant Proc. Author manuscript; available in PMC 2011 April 6. NIH Public Access Author Manuscript Published in final edited form as: Transplant Proc. 1991 December ; 23(6): 2777 2779. Pharmacokinetics of Cyclosporine and Nephrotoxicity in Orthotopic Liver Transplant

More information

Inhibition of Human Hepatic Bile Acid Transporters as Contributing Factors to Drug-Induced Liver Injury

Inhibition of Human Hepatic Bile Acid Transporters as Contributing Factors to Drug-Induced Liver Injury Inhibition of Human Hepatic Bile Acid Transporters as Contributing Factors to Drug-Induced Liver Injury Kenneth R. Brouwer, Ph.D., RPh Chief Scientific Officer DDI Meeting June 2017 Seattle, Washington

More information

Application of PBPK Modeling and Simulations in Drug Development

Application of PBPK Modeling and Simulations in Drug Development Application of PBPK Modeling and Simulations in Drug Development Ping Zhao Division of Pharmacometrics Office of Clinical Pharmacology Office of Translational Sciences Center for Drug Evaluation and Research

More information

Montpellier and Nimes University Hospital. 2nd International Workshop on Clinical Pharmacology of Anticancer Drugs Madrid, September the 13th and 14th

Montpellier and Nimes University Hospital. 2nd International Workshop on Clinical Pharmacology of Anticancer Drugs Madrid, September the 13th and 14th Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer Litaty MBATCHI, Matthieu GASSIOT,

More information

Cytochrome P450 interactions

Cytochrome P450 interactions Cytochrome P450 interactions Learning objectives After completing this activity, pharmacists should be able to: Explain the mechanism of action of clopidogrel-ppi interaction Assess the risks and benefits

More information

NIH Public Access Author Manuscript Drug Metab Dispos. Author manuscript; available in PMC 2009 January 1.

NIH Public Access Author Manuscript Drug Metab Dispos. Author manuscript; available in PMC 2009 January 1. NIH Public Access Author Manuscript Published in final edited form as: Drug Metab Dispos. 2008 January ; 36(1): 61 64. doi:10.1124/dmd.107.017319. Multidrug Resistance-Associated Protein 2 (Mrp2) is Primarily

More information

Drug Absorption and Bioavailability

Drug Absorption and Bioavailability Drug Absorption and Bioavailability Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program October 1, 2015 Office of Clinical Research Training and Medical Education National Institutes

More information

Drug Absorption and Bioavailability

Drug Absorption and Bioavailability Drug Absorption and Bioavailability Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program October 1, 2015 Office of Clinical Research Training and Medical Education National Institutes

More information

Prediction of the Effects of Renal Impairment on the Clearance for Organic Cation Drugs that. undergo Renal Secretion: A Simulation-Based Study

Prediction of the Effects of Renal Impairment on the Clearance for Organic Cation Drugs that. undergo Renal Secretion: A Simulation-Based Study DMD Fast Forward. Published on February 28, 2018 as DOI: 10.1124/dmd.117.079558 This article has not been copyedited and formatted. The final version may differ from this version. Prediction of the Effects

More information

Critical review of the literature on drug interactions

Critical review of the literature on drug interactions Critical review of the 2015-2016 literature on drug interactions Katie Owens, BPharm PhD Research Scientist II Drug Interaction Database (DIDB) Program Dept. of Pharmaceutics University of Washington 19

More information

Drug disposition classification systems: A comparative review of BDDCS, ECCS and ECCCS

Drug disposition classification systems: A comparative review of BDDCS, ECCS and ECCCS Novartis Drug disposition classification systems: A comparative review of BDDCS, ECCS and ECCCS Birk Poller, Gian Camenisch - Novartis SOLVO - Meet The Experts Transporter Conference April 26, 2018 Drug

More information

TDM. Measurement techniques used to determine cyclosporine level include:

TDM. Measurement techniques used to determine cyclosporine level include: TDM Lecture 15: Cyclosporine. Cyclosporine is a cyclic polypeptide medication with immunosuppressant effect. It has the ability to block the production of interleukin-2 and other cytokines by T-lymphocytes.

More information

PBPK modeling of renal impairment what is missing?

PBPK modeling of renal impairment what is missing? PBPK modeling of renal impairment what is missing? Aleksandra Galetin Centre for Applied Pharmacokinetic Research, University of Manchester, UK Outline of the presentation Physiological changes in renal

More information

PRUCAPLA Tablets (Prucalopride)

PRUCAPLA Tablets (Prucalopride) Published on: 2 May 2018 PRUCAPLA Tablets (Prucalopride) Composition PRUCAPLA 1 mg Each film coated tablet contains: Prucalopride succinate equivalent to Prucalopride 1 mg Excipients. q. s. Color: Titanium

More information

Pharmacokinetics for Physicians. Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne

Pharmacokinetics for Physicians. Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne Pharmacokinetics for Physicians Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne The Important Therapeutic Questions What drug? What dose? How long? Drug Dosage

More information

DRUG-DRUG INTERACTIONS OF GLECAPREVIR AND PIBRENTASVIR WITH PRAVASTATIN, ROSUVASTATIN, OR DABIGATRAN ETEXILATE

DRUG-DRUG INTERACTIONS OF GLECAPREVIR AND PIBRENTASVIR WITH PRAVASTATIN, ROSUVASTATIN, OR DABIGATRAN ETEXILATE DRUG-DRUG INTERACTIONS OF GLECAPREVIR AND PIBRENTASVIR WITH PRAVASTATIN, ROSUVASTATIN, OR DABIGATRAN ETEXILATE Matthew P. Kosloski, Weihan Zhao, Hong Li, Stanley Subhead Wang, Calibri Joaquin 14pt, Valdes,

More information

Click to edit Master title style

Click to edit Master title style A Short Course in Pharmacokinetics Chris Town Research Pharmacokinetics Outline Pharmacokinetics - Definition Ideal Pharmacokinetic Parameters of a New Drug How do we optimize PK for new compounds Why

More information

Variability Due to Genetic Differences

Variability Due to Genetic Differences 1 Variability Due to Genetic Differences Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland 2 Objectives Understand how between individual variation may contribute to :» drug

More information

Physiologically-Based Simulation of Daclatasvir Pharmacokinetics With Antiretroviral Inducers and Inhibitors of Cytochrome P450 and Drug Transporters

Physiologically-Based Simulation of Daclatasvir Pharmacokinetics With Antiretroviral Inducers and Inhibitors of Cytochrome P450 and Drug Transporters Physiologically-Based Simulation of Daclatasvir Pharmacokinetics With Antiretroviral Inducers and Inhibitors of Cytochrome P450 and Drug Transporters Qi Wang, Wenying Li, Ming Zheng, Timothy Eley, Frank

More information

Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin

Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin Citation: CPT Pharmacometrics Syst. Pharmacol. (2017) 6, 228 238; VC 2017 ASCPT All rights reserved doi:10.1002/psp4.12168 ORIGINAL ARTICLE Investigating Transporter-Mediated Drug-Drug Interactions Using

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Chen CL, Lin GA, Bardach NS, et al. Preoperative medical testing

More information

Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 4, 2010 National

Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 4, 2010 National Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 4, 2010 National Institutes of Health Clinical Center GOALS of Liver Disease

More information

Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program October 29, 2015 National

Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program October 29, 2015 National Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program October 29, 2015 National Institutes of Health Clinical Center GOALS of Liver Disease

More information

Drug Interactions: Definition

Drug Interactions: Definition Drug Interactions Scott R. Penzak, Pharm.D. Director, Clinical Pharmacokinetics Research Laboratory Clinical Center Pharmacy Department National Institutes of Health December 9, 2010 Drug Interactions:

More information

Current Approaches and Applications of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters

Current Approaches and Applications of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters Current Approaches and Applications of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters Uwe Fuhr, University Hospital Cologne 1 Definition Phenotyping is quantifying the in vivo activity

More information

Mycophénolate mofétil

Mycophénolate mofétil Mycophénolate mofétil O OH CH 3 O O-desmethyl O glucosides OH CH 3 OCH 3 CH 3 CYP 3A UGT2B7 C O HO O HO AcMPAG (acyl-glucuronide) ACTIF TOXIQUE O O CH 3 OCH 3 Mycophenolate (MPA) OH COOH UGT enzymes COOH

More information

Metformin Associated Lactic Acidosis. Jun-Ki Park 9/6/11

Metformin Associated Lactic Acidosis. Jun-Ki Park 9/6/11 Metformin Associated Lactic Acidosis Jun-Ki Park 9/6/11 Probably the most common mechanism by which metformin elevates blood lactate is by inducing catecholamine release in those who regulate or prescribe

More information

MEDCHEM 570. First Midterm. January 30, 2015

MEDCHEM 570. First Midterm. January 30, 2015 Name MEDCHEM 570 First Midterm January 30, 2015 Instructions: Exam packet totals 7 pages. The last page has a 5 points extra credit question. If you need additional space for a question go to the back

More information

14 41 minutes Vd 218 t ½ 22 to 70 Clearance hours Protein Binding 71%, active metabolite 42% Bioavailability 3%

14 41 minutes Vd 218 t ½ 22 to 70 Clearance hours Protein Binding 71%, active metabolite 42% Bioavailability 3% Brand Name: Yupelri Generic Name: revefenacin Manufacturer: Mylan Drug Class: Anticholinergic Uses: Labeled Uses: inhalation solution for maintenance treatment of COPD 1 Unlabeled Uses: no off-label indications

More information

NIH Public Access Author Manuscript Clin Pharmacol Ther. Author manuscript; available in PMC 2010 November 9.

NIH Public Access Author Manuscript Clin Pharmacol Ther. Author manuscript; available in PMC 2010 November 9. NIH Public Access Author Manuscript Published in final edited form as: Clin Pharmacol Ther. 2008 February ; 83(2): 273 280. doi:10.1038/sj.clpt.6100275. Effect of Genetic Variation in the Organic Cation

More information

Building innovative drug discovery alliances. Hepatic uptake and drug disposition o in vitro and in silico approaches

Building innovative drug discovery alliances. Hepatic uptake and drug disposition o in vitro and in silico approaches Building innovative drug discovery alliances Hepatic uptake and drug disposition o in vitro and in silico approaches Dr Beth Williamson Evotec AG, 2017 Outline Importance of predicting clearance In vitro

More information

Fundamentals of Membrane Transporters and their Role in In Vivo PK/PD of Drugs

Fundamentals of Membrane Transporters and their Role in In Vivo PK/PD of Drugs Fundamentals of Membrane Transporters and their Role in In Vivo PK/PD of Drugs Jash Unadkat, Ph.D. Department of Pharmaceutics University of Washington Seattle, WA 98195 http://depts.washington.edu/pceut/faculty_research/faculty_members/unadkat_jashvant.html

More information

DOSING AND ADMINISTRATION GUIDE

DOSING AND ADMINISTRATION GUIDE DOSING AND ADMINISTRATION GUIDE Indication TAVALISSE is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient

More information

Renal Impairment From Dettli to Guideline: What can we learn?

Renal Impairment From Dettli to Guideline: What can we learn? Renal Impairment From Dettli to Guideline: What can we learn? SocraMetrics GmbH Mainzerhofplatz 14 99084 Erfurt phone: ++49-361-6020526 fax: ++49-361-6020525 e-mail: meinolf.wonnemann@socrametrics.de SocraMetrics

More information

In vitro substrate-dependent inhibition of OATP1B1 and its impact on DDI prediction

In vitro substrate-dependent inhibition of OATP1B1 and its impact on DDI prediction SSX 3 rd Annual Conference (Oct 11, 2018) In vitro substrate-dependent inhibition of OATP1B1 and its impact on DDI prediction Yoshitane Nozaki, PhD DMPK Tsukuba Organic Anion Transporting Polypeptide (OATP)

More information

The effect of telaprevir on the pharmacokinetics of CYP3A and P-gp substrates

The effect of telaprevir on the pharmacokinetics of CYP3A and P-gp substrates The effect of telaprevir on the pharmacokinetics of CYP3A and P-gp substrates Varun Garg, PhD On behalf of Drs. N Adda, K Alves, G Chandorkar, J-E Lee, X Luo, F Smith, R van Heeswijk, and Y Yang Author

More information

Use of in vitro cell assays and noninvasive imaging techniques to reduce animal experiments in drug development

Use of in vitro cell assays and noninvasive imaging techniques to reduce animal experiments in drug development Use of in vitro cell assays and noninvasive imaging techniques to reduce animal experiments in drug development J. Jia, M. Keiser, S. Oswald, W. Siegmund Department of Clinical Pharmacology, Ernst-Moritz-Arndt

More information

Original article: EFFECT OF CLOPIDOGREL ON THE HYDROXYLATION AND SULFOXIDATION OF OMEPRAZOLE: A SINGLE DOSE STUDY IN HEALTHY HUMAN VOLUNTEERS

Original article: EFFECT OF CLOPIDOGREL ON THE HYDROXYLATION AND SULFOXIDATION OF OMEPRAZOLE: A SINGLE DOSE STUDY IN HEALTHY HUMAN VOLUNTEERS Original article: EFFECT OF CLOPIDOGREL ON THE HYDROXYLATION AND SULFOXIDATION OF OMEPRAZOLE: A SINGLE DOSE STUDY IN HEALTHY HUMAN VOLUNTEERS Lateef Ahmad 1, Zafar Iqbal 2, Shabnam Nazir 3 *, Abad Khan

More information

Understanding Blood Tests

Understanding Blood Tests PATIENT EDUCATION patienteducation.osumc.edu Your heart pumps the blood in your body through a system of blood vessels. Blood delivers oxygen and nutrients to all parts of the body. It also carries away

More information

Hepatic Efflux Transporters: Relevance to Drug-Drug Interactions and Drug Toxicity

Hepatic Efflux Transporters: Relevance to Drug-Drug Interactions and Drug Toxicity Hepatic Efflux Transporters: Relevance to Drug-Drug Interactions and Drug Toxicity Kim L. R. Brouwer, PharmD, PhD W.R. Kenan, Jr., Distinguished Professor Associate Dean for Research and Graduate Education

More information

PRODUCT CIRCULAR CASPOFUNGIN. Antifungal

PRODUCT CIRCULAR CASPOFUNGIN. Antifungal PRODUCT CIRCULAR CASPOFUNGIN CANCIDAS Powder for I.V. Injection Antifungal THERAPEUTIC CLASS CASPOFUNGIN (CANCIDAS ) is a sterile, lyophilized product for intravenous infusion that contains a semi-synthetic

More information

2/28/2010. Pharmacogenomics and the Asian Population. Limited efficacy/response to drugs already on the market

2/28/2010. Pharmacogenomics and the Asian Population. Limited efficacy/response to drugs already on the market Pharmacogenomics and the Asian Population Majority are medication related Alan H.B. Wu, Ph.D. Professor, Laboratory Medicine, UCSF Section Chief, Clinical Chemistry, February 27, 20 Limited efficacy/response

More information

PHA5128 Dose Optimization II Case Study I Spring 2013

PHA5128 Dose Optimization II Case Study I Spring 2013 Silsamicin is an investigational compound being evaluated for its antimicrobial effect. The route of administration for this drug is via intravenous bolus. Approximately 99.9% of this drug is eliminated

More information

PHA First Exam. Fall 2004

PHA First Exam. Fall 2004 PHA 5127 First Exam Fall 2004 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Put all answers on the bubble sheet. If you need to comment or question a problem

More information